142 related articles for article (PubMed ID: 18201272)
1. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
Taguchi E; Nakamura K; Miura T; Shibuya M; Isoe T
Cancer Sci; 2008 Mar; 99(3):623-30. PubMed ID: 18201272
[TBL] [Abstract][Full Text] [Related]
2. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
[TBL] [Abstract][Full Text] [Related]
3. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.
Masoumi Moghaddam S; Amini A; Morris DL; Pourgholami MH
Cancer Metastasis Rev; 2012 Jun; 31(1-2):143-62. PubMed ID: 22101807
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis.
Stoeltzing O; Ahmad SA; Liu W; McCarty MF; Parikh AA; Fan F; Reinmuth N; Bucana CD; Ellis LM
Br J Cancer; 2002 Nov; 87(10):1182-7. PubMed ID: 12402160
[TBL] [Abstract][Full Text] [Related]
5. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
6. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.
Tokuyama J; Kubota T; Saikawa Y; Yoshida M; Furukawa T; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2005; 25(1A):17-22. PubMed ID: 15816514
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Xu L; Yoneda J; Herrera C; Wood J; Killion JJ; Fidler IJ
Int J Oncol; 2000 Mar; 16(3):445-54. PubMed ID: 10675474
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
10. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Manenti L; Riccardi E; Marchini S; Naumova E; Floriani I; Garofalo A; Dossi R; Marrazzo E; Ribatti D; Scanziani E; Bani M; Belotti D; Broggini M; Giavazzi R
Mol Cancer Ther; 2005 May; 4(5):715-25. PubMed ID: 15897235
[TBL] [Abstract][Full Text] [Related]
11. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Matsui J; Yamamoto Y; Funahashi Y; Tsuruoka A; Watanabe T; Wakabayashi T; Uenaka T; Asada M
Int J Cancer; 2008 Feb; 122(3):664-71. PubMed ID: 17943726
[TBL] [Abstract][Full Text] [Related]
12. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic vascular growth in the rat peritoneal disseminated tumor model.
Yanagi K; Ohshima N
Microvasc Res; 1996 Jan; 51(1):15-28. PubMed ID: 8812750
[TBL] [Abstract][Full Text] [Related]
14. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) expression regulates angiogenesis accompanying tumor growth in a peritoneal disseminated tumor model.
Miyoshi C; Ohshima N
In Vivo; 2001; 15(3):233-8. PubMed ID: 11491018
[TBL] [Abstract][Full Text] [Related]
17. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.
Shaheen RM; Ahmad SA; Liu W; Reinmuth N; Jung YD; Tseng WW; Drazan KE; Bucana CD; Hicklin DJ; Ellis LM
Br J Cancer; 2001 Aug; 85(4):584-9. PubMed ID: 11506500
[TBL] [Abstract][Full Text] [Related]
18. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
19. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]